CPI-268456 is an inhibitor of bromodomain-containing protein 4 (BRD4), binding to BRD4 (IC50 =<0.5 µM in a cell-free assay) and inhibiting LPS-induced IL-6 secretion in THP-1 cells (IC50 = <0.5 µM).

(+)-JQ1 PA (also known as (+)-JQ1 propargyl amide) is a novel propargyl amide derivative of (+)-JQ1 with IC50 of 10.4 nM for Bromodomain and extra-terminal (BET).

KG-501 is a potent inhibitor of CREB (cAMP response element-binding protein) with an IC50 of 6.89 μM.

FL-411 is a potent and selective BRD4 inhibitor with an IC50 of 0.43±0.09 μM for BRD4(1).

EED226 (EED-226) is a first-in-class, selective, orally bioavailable and allosteric inhibitor of embryonic ectoderm development (EED) with potential anticancer activity.

(R)-BAY1238097 is the R-isomer of BAY-1238097 with lower activity than BAY1238097.

Thalidomide-NH-C4-NH-Boc (compound 15) is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.

BETd-246 is a novel, potent and second-generation BET bromodomain (BRD) degrader which exhibits superior selectivity, potency and antitumor activity.

PFI-3 (PFI3) is a potent, selective, acetyl-lysine-competitive, and cell-permeable inhibitor of SMARCA bromodomains (SMARCA2/4 and PB1(5)) with antineoplastic activity.

OF-1 (OF1; SGC-OF-1) is a potent and selective inhibitor of bromodomain and PHD finger containing protein 1 (BRPF1) with important biological activity.